Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,879,723
  • Shares Outstanding, K 238,734
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 152 M
  • EBITDA $ 161 M
  • 60-Month Beta 0.57
  • Price/Sales 11.30
  • Price/Cash Flow 36.38
  • Price/Book 12.58

Options Overview Details

View History
  • Implied Volatility 48.62% ( +0.92%)
  • Historical Volatility 76.68%
  • IV Percentile 13%
  • IV Rank 25.97%
  • IV High 112.27% on 08/06/24
  • IV Low 26.30% on 06/12/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 1,891
  • Volume Avg (30-Day) 7,756
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 86,571
  • Open Int (30-Day) 82,688

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.14
  • Number of Estimates 1
  • High Estimate 0.14
  • Low Estimate 0.14
  • Prior Year 0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.75 +9.01%
on 05/08/25
25.67 -20.37%
on 04/28/25
-0.87 (-4.08%)
since 04/17/25
3-Month
13.50 +51.41%
on 03/04/25
25.67 -20.37%
on 04/28/25
+4.36 (+27.11%)
since 02/20/25
52-Week
9.31 +119.55%
on 05/21/24
25.67 -20.37%
on 04/28/25
+11.03 (+117.22%)
since 05/20/24

Most Recent Stories

More News
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates

Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss...

IMCR : 32.39 (+4.48%)
PBYI : 3.63 (+1.40%)
ADMA : 20.44 (+1.24%)
ANIP : 60.64 (+0.80%)
Adma Biologics: Q1 Earnings Snapshot

Adma Biologics: Q1 Earnings Snapshot

ADMA : 20.44 (+1.24%)
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

ADMA : 20.44 (+1.24%)
3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

PEN : 281.13 (-0.15%)
ADMA : 20.44 (+1.24%)
TMDX : 124.71 (+2.14%)
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome Therapeutics AXSM incurred an adjusted loss of $1.22 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.26. The company had incurred a loss of $1.44...

IMCR : 32.39 (+4.48%)
JAZZ : 111.02 (+1.13%)
ADMA : 20.44 (+1.24%)
AXSM : 108.35 (+0.05%)
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

Alkermes plc ALKS reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
ADMA : 20.44 (+1.24%)
ALKS : 31.67 (+0.70%)
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had reported...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
AGIO : 30.17 (+1.11%)
ADMA : 20.44 (+1.24%)
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down

Shares of Bausch Health Companies Inc. BHC declined 3.81% after the company reported lower-than-expected first-quarter 2025 results.Adjusted earnings per share of 59 cents missed the Zacks Consensus Estimate...

BEAM : 17.75 (+0.54%)
FOLD : 6.59 (+2.65%)
ADMA : 20.44 (+1.24%)
BHC : 4.68 (+0.86%)
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas

For Immediate ReleaseChicago, IL – May 1, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

LTH : 29.30 (-0.37%)
LRN : 157.46 (+0.32%)
ADMA : 20.44 (+1.24%)
FCFS : 127.13 (-0.80%)
NFG : 81.30 (-0.12%)
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Repligen Corporation RGEN reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
RGEN : 127.59 (+1.11%)
ADMA : 20.44 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 21.46
2nd Resistance Point 20.99
1st Resistance Point 20.71
Last Price 20.44
1st Support Level 19.96
2nd Support Level 19.49
3rd Support Level 19.21

See More

52-Week High 25.67
Last Price 20.44
Fibonacci 61.8% 19.42
Fibonacci 50% 17.49
Fibonacci 38.2% 15.56
52-Week Low 9.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »